Serotonin 1A receptors in the pathophysiology of schizophrenia: Development of novel cognition-enhancing therapeutics

Advances in Therapy

Volumn 25, Issue 10, 2008, Pages 1037-1056

  Sumiyoshi, Tomiki ^a   Bubenikova Valesova, Vera ^b   Horacek, Jiri ^b   Bert, Bettina ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

5 HT receptors; 5 HT 1A; Cognition; Schizophrenia; Serotonin; Translational research

Indexed keywords

BUSPIRONE; ISOINDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER; TANDOSPIRONE;

ANIMAL; BEHAVIOR; BRAIN; COGNITIVE DEFECT; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

ANIMALS; BEHAVIOR; BRAIN; BUSPIRONE; COGNITION DISORDERS; HUMANS; ISOINDOLES; PIPERAZINES; POLYMORPHISM, GENETIC; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 61749086565     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0102-2     Document Type: Article

References (84)

1. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618-624.
2. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology 8th Edition. Oxford: Oxford University Press; 2003.
3. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19:123-132. (Pubitemid 28288438)
4. Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol. 2008;11:701-721. (Pubitemid 351931817)
5. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159-1172. (Pubitemid 37464960)
6. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol. 2004;7:1-8. (Pubitemid 38523801)
7. Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol. 2005;8:451-455. (Pubitemid 41002499)
8. Sumiyoshi T, Meltzer HY. Serotonin 1A receptors in memory function. Am J Psychiatry. 2004;161:1505.
9. Palchaudhuri M, Flugge G. 5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res. 2005;321:159-172. (Pubitemid 41127024)
10. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193-203. (Pubitemid 36135929)
11. Blier P, Lista A, De Montigny C. Differential properties of pre-and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther. 1993;265:16-23. (Pubitemid 23320936)
12. Hjorth S, Magnusson T. The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1988;338:463-471. (Pubitemid 19014451)
13. Hensler JG, Ladenheim EE, Lyons WE. Ethanol consumption and serotonin-1A (5-HT1A) receptor function in heterozygous BDNF (+/-) mice. J Neurochem. 2003;85:1139-1147. (Pubitemid 36613262)
14. Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol. 1989;96:283-290. (Pubitemid 19045101)
15. Kreiss DS, Lucki I. Chronic administration of the 5-HT1A receptor agonist 8-OHDPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse. 1997;25:107-116. (Pubitemid 27121221)
16. Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(-1019) G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004;7:441-451. (Pubitemid 39648074)
17. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;163:1826-1829. (Pubitemid 44522494)
18. Hurlemann R, Boy C, Meyer PT, et al. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl). 2005;210:519-523. (Pubitemid 41752613)
19. Unschuld PG, Ising M, Erhardt A, et al. Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:424-429. (Pubitemid 46983148)
20. Erdmann J, Shimron-Abarbanell D, Rietschel M, et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet. 1996;97:614-619.
21. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet. 1996;347:1294-1296.
22. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002;67:812-822. (Pubitemid 34226294)
23. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995;346:281-282.
24. Dubertret C, Hanoun N, Ades J, Hamon M, Gorwood P. Family-based association study of the 5-HT transporter gene and schizophrenia. Int J Neuropsychopharmacol. 2005;8:87-92. (Pubitemid 40388817)
25. Fan JB, Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry. 2005;10:928-938. (Pubitemid 41486485)
26. Pae CU, Artioli P, Serretti A, et al. No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. Neurosci Res. 2005;52:195-199. (Pubitemid 40704602)
27. Chotai J, Serretti A, Lorenzi C. Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. Neuropsychobiology. 2005;51:3-9. (Pubitemid 40867984)
28. Pae CU, Kim JJ, Lee SJ, et al. Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. Neuropsychobiology. 2003;47:182-186.
29. Wasserman D, Geijer T, Sokolowski M, et al. Association of the serotonin transporter promotor polymorphism with suicide attempters with a high medical damage. Eur Neuropsychopharmacol. 2007;17:230-233. (Pubitemid 44779198)
30. Horacek J. The influence of polymorphism for serotonin 5-HT1A receptors on phenotypic variables in schizophrenia. Presented at the 16th European Congress of Psychiatry; April 7, 2008; Nice, France. Symposium: "Role of serotonin-5-HT1A receptors in the pathophysiology and treatment of schizophrenia".
31. Buchsbaum MS, Hazlett EA. Functional brain imaging and aging in schizophrenia. Schizophr Res. 1997;27:129-141. (Pubitemid 27512850)
32. Sumiyoshi T, Higuchi Y, Ito T, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res Neuroimaging. In press.
33. Sumiyoshi T, Higuchi Y, Matsui M, et al. Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:965-967. (Pubitemid 46660309)
34. Sumiyoshi T, Matsui M, Itoh H, et al. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res. 2008;157:87-93. (Pubitemid 350166534)
35. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95:158-168. (Pubitemid 47313647)
36. Gu Z, Jiang Q, Yan Z. RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol. 2007;71:1030-1039. (Pubitemid 46457007)
37. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7-61. (Pubitemid 29113865)
38. Calcagno E, Carli M, Invernizzi RW. The 5-HT1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem. 2006;96:853-860.
39. Madjid N, Tottie EE, Luttgen M, et al. 5-hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther. 2006;316:581-591. (Pubitemid 43130984)
40. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32:1014-1023. (Pubitemid 351756510)
41. Andine P, Widermark N, Axelsson R, et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther. 1999;290:1393-1408. (Pubitemid 29400285)
42. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001;156:117-154. (Pubitemid 32702206)
43. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2007;32:2087-2097. (Pubitemid 47417703)
44. Bubenikova-Valesova V, Votava M, Palenicek T, Horacek J. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology. 2007;52:1071-1078. (Pubitemid 46321545)
45. Maj J, Rogoz Z, Skuza G, Wedzony K. The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J Neural Transm. 1996;103:131-146.
46. Dall'Olio R, Gaggi R, Bonfante V, Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol. 1999;10:63-71. (Pubitemid 29106289)
47. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158:1722-1725. (Pubitemid 32923670)
48. Sumiyoshi T, Matsui M, Yamashita I, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000;20:386-388. (Pubitemid 30318373)
49. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl). 2004;174:17-24. (Pubitemid 38925086)
50. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15:37-46. (Pubitemid 32242102)
51. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry. 2001;49:861-868. (Pubitemid 32436390)
52. Kusserow H, Davies B, Hortnagl H, et al. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. Mol Brain Res. 2004;129:104-116. (Pubitemid 39304254)
53. Bert B, Fink H, Hortnagl H, et al. Mice over-expressing the 5-HT1A receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT. Behav Brain Res. 2006;167:328-341. (Pubitemid 43099794)
54. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 1985;346:205-230. (Pubitemid 16241111)
55. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff "? Schizophr Bull. 2000;26:119-136. (Pubitemid 30317696)
56. Meeter M, Talamini L, Schmitt JA, Riedel WJ. Effects of 5-HT on memory and the hippocampus: model and data. Neuropsychopharmacology. 2006;31:712-720.
57. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCPinduced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res. 2007;184:31-38. (Pubitemid 47404650)
58. Bubenikova-Valesova V, Stuchlik A, Svoboda J, Bures J, Vales K. Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proc Natl Acad Sci USA. 2008;105:1061-1066. (Pubitemid 351282081)
59. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25:10831-10843. (Pubitemid 41692613)
60. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531. (Pubitemid 32198256)
61. Sato M, Ago Y, Koda K, et al. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol. 2007;559:155-160. (Pubitemid 46295406)
62. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996;15:442-455. (Pubitemid 26389868)
63. Burnet PW, Eastwood SL, Harrison PJ. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int. 1997;30:565-574. (Pubitemid 27187227)
64. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry. 1997;42:529-545. (Pubitemid 27425471)
65. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991;48:355-363.
66. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993;8:315-336. (Pubitemid 23162958)
67. Simpson MDC, Lubman DI, Slater P, Deakin JFW. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry. 1996;39:919-928.
68. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996;708:209-214.
69. Kasper S, Tauscher J, Willeit M, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry. 2002;3:133-146.
70. Tauscher J, Meyer JH, Smith GS, Rabiner EA. Imaging of the serotonin system in depression and schizophrenia. Biol Psychiatry. 2002;51:146S.
71. Hamik A, Oksenberg D, Fischette C, Peroutka SJ. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990;28:99-109. (Pubitemid 20226391)
72. Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol. 1992;12:341-345.
73. Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int J Neuropsychopharmacol. 2006;9:677-683. (Pubitemid 46122767)
74. Araki T, Yamasue H, Sumiyoshi T, et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:204-208. (Pubitemid 43288059)
75. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033-2046.
76. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005;1043:32-41. (Pubitemid 40603369)
77. Uehara T, Sumiyoshi T, Matsuoka T, Itoh H, Kurachi M. Role of 5-HT1A receptors in the modulation of stressinduced lactate metabolism in the medial prefrontal cortex and basolateral amygdala. Psychopharmacology (Berl). 2006;186:218-225. (Pubitemid 43727339)
78. Hagiwara H, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008;18:448-454.
79. Luttgen M, Ogren SO, Meister B. 5-HT1A receptor mRNA and immunoreactivity in the rat medial septum/diagonal band of Broca-relationships to GABAergic and cholinergic neurons. J Chem Neuroanat. 2005;29:93-111. (Pubitemid 40126685)
80. Schiapparelli L, Simon AM, Del Rio J, Frechilla D. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology. 2006;50:897-907. (Pubitemid 43737006)
81. Boulay D, Depoortere R, Louis C, Perrault G, Griebel G, Soubrie P. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology. 2004;46:1121-1129. (Pubitemid 38529936)
82. Depoortere R, Bardin L, Auclair AL, et al. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Br J Pharmacol. 2007;151:253-265. (Pubitemid 46763036)
83. McCreary AC, Glennon JC, Ashby CR Jr, et al. SLV313 (1-(2,3-dihydrobenzo[ 1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology. 2007;32:78-94. (Pubitemid 44967786)
84. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 2007;8:539-554. (Pubitemid 47016322)